Daridorexant for the Treatment of Insomnia
# Purpose of Review Insomnia is a complex sleeping disorder that affects the lives of many individuals worldwide. Insomnia often occurs in the presence of coexisting comorbidities making it a complex disorder that requires a multifactorial approach to therapy. First-line therapy is cognitive-behavi...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Medical Publishing
2022-08-01
|
| Series: | Health Psychology Research |
| Online Access: | https://doi.org/10.52965/001c.37400 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825139365673697280 |
|---|---|
| author | Christopher L Robinson Rajesh Supra Evan Downs Saurabh Kataria Katelyn Parker Alan D. Kaye Omar Viswanath Ivan Urits |
| author_facet | Christopher L Robinson Rajesh Supra Evan Downs Saurabh Kataria Katelyn Parker Alan D. Kaye Omar Viswanath Ivan Urits |
| author_sort | Christopher L Robinson |
| collection | DOAJ |
| description | # Purpose of Review
Insomnia is a complex sleeping disorder that affects the lives of many individuals worldwide. Insomnia often occurs in the presence of coexisting comorbidities making it a complex disorder that requires a multifactorial approach to therapy. First-line therapy is cognitive-behavioral therapy for insomnia (CBT-I). Pharmacotherapy for insomnia falls into four classes based on mechanism of action: benzodiazepine receptor agonists (BZRAs), histamine receptor antagonists, melatonin receptor agonists, and dual orexin receptor antagonists (DORAs).
# Recent Findings
Daridorexant is a dual orexin type 1 and types 2 (OX~1~ and OX~2~) receptor antagonist that was recently approved by the US FDA for the treatment of adults suffering from insomnia. It was shown to be effective in reducing insomnia symptoms, increasing daytime functioning, and improving the overall quality of sleep. Daridorexant offers patients relief from insomnia while avoiding the severe side effects and dependency issues of traditional treatments like benzodiazepines and sedatives.
# Summary
In this article, we review the most recent data on insomnia treatments and summarize the safety and efficacy of daridorexant in treating insomnia. |
| format | Article |
| id | doaj-art-f1b7b06e934b4b2995c320cfcd72b98e |
| institution | Kabale University |
| issn | 2420-8124 |
| language | English |
| publishDate | 2022-08-01 |
| publisher | Open Medical Publishing |
| record_format | Article |
| series | Health Psychology Research |
| spelling | doaj-art-f1b7b06e934b4b2995c320cfcd72b98e2025-02-11T20:30:41ZengOpen Medical PublishingHealth Psychology Research2420-81242022-08-01103Daridorexant for the Treatment of InsomniaChristopher L RobinsonRajesh SupraEvan DownsSaurabh KatariaKatelyn ParkerAlan D. KayeOmar ViswanathIvan Urits# Purpose of Review Insomnia is a complex sleeping disorder that affects the lives of many individuals worldwide. Insomnia often occurs in the presence of coexisting comorbidities making it a complex disorder that requires a multifactorial approach to therapy. First-line therapy is cognitive-behavioral therapy for insomnia (CBT-I). Pharmacotherapy for insomnia falls into four classes based on mechanism of action: benzodiazepine receptor agonists (BZRAs), histamine receptor antagonists, melatonin receptor agonists, and dual orexin receptor antagonists (DORAs). # Recent Findings Daridorexant is a dual orexin type 1 and types 2 (OX~1~ and OX~2~) receptor antagonist that was recently approved by the US FDA for the treatment of adults suffering from insomnia. It was shown to be effective in reducing insomnia symptoms, increasing daytime functioning, and improving the overall quality of sleep. Daridorexant offers patients relief from insomnia while avoiding the severe side effects and dependency issues of traditional treatments like benzodiazepines and sedatives. # Summary In this article, we review the most recent data on insomnia treatments and summarize the safety and efficacy of daridorexant in treating insomnia.https://doi.org/10.52965/001c.37400 |
| spellingShingle | Christopher L Robinson Rajesh Supra Evan Downs Saurabh Kataria Katelyn Parker Alan D. Kaye Omar Viswanath Ivan Urits Daridorexant for the Treatment of Insomnia Health Psychology Research |
| title | Daridorexant for the Treatment of Insomnia |
| title_full | Daridorexant for the Treatment of Insomnia |
| title_fullStr | Daridorexant for the Treatment of Insomnia |
| title_full_unstemmed | Daridorexant for the Treatment of Insomnia |
| title_short | Daridorexant for the Treatment of Insomnia |
| title_sort | daridorexant for the treatment of insomnia |
| url | https://doi.org/10.52965/001c.37400 |
| work_keys_str_mv | AT christopherlrobinson daridorexantforthetreatmentofinsomnia AT rajeshsupra daridorexantforthetreatmentofinsomnia AT evandowns daridorexantforthetreatmentofinsomnia AT saurabhkataria daridorexantforthetreatmentofinsomnia AT katelynparker daridorexantforthetreatmentofinsomnia AT alandkaye daridorexantforthetreatmentofinsomnia AT omarviswanath daridorexantforthetreatmentofinsomnia AT ivanurits daridorexantforthetreatmentofinsomnia |